Introduction
Myeloproliferative neoplasms (MPN) carrying fibroblast growth factor receptor-1 (FGFR1) fusion genes are rare, stem cell disorders that are clinically characterized by eosinophilia, a poor prognosis and frequent association with T-or B-cell lymphoma. FGFR1 is most commonly fused to ZMYM2 (ZNF198) as a result of the t(8;13)(p11;q12) but rearrangements involving BCR, FGFR1OP, FGFR1OP2, CEP110, TRIM24, MYO18A, CFS1, LRRFIP1 and CUX1 have also been described, some as single cases. [1] [2] [3] These fusions are all associated with cytogenetically visible rearrangements of 8p11-12 and thus the disorder is commonly referred to as the 8p11 myeloproliferative syndrome (EMS).
Stem cell transplantation is currently the only curative treatment for EMS and although a number of compounds have been investigated for activity against FGFR1 fusion proteins, 2, [4] [5] [6] [7] none are routinely available for clinical use.
Ponatinib (AP24534) has previously been shown to have inhibitory activity towards FGFRs.
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Here we confirm its activity in cell line models and have further investigated its potential for the treatment of EMS patients using primary patient material.
Design and Methods

Cell line assays
The Ba/F3 cell lines transformed to interleukin-3 (IL3) independence by pcDNA3.1-BCR-FGFR1 (Ba/F3-BF) or pcDNA3-1-ZMYM2-FGFR1 (Ba/F3-ZF) are described elsewhere.
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We focused on these two fusions as they are the ones most frequently seen in EMS patients.
Cells lines were grown in RPMI-1640 plus either 10% serum (HL60, HEL and transformed Ba/F3 cell lines), 20% serum (KG1A) or 10% serum plus 10% WEHI-conditioned medium as a source of IL3 (Ba/F3-A10, a non-transformed Ba/F3 cell line containing the pcDNA3.1 vector). Ponatinib (AP24534) was supplied by Ariad Pharmaceuticals Inc., dissolved in dimethyl sulfoxide (10 mM) and stored at -20°C in single-use aliquots.
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To assess proliferative response to ponatinib, cell lines were set up at 1 and anti-phospho-FGFR1 (#3476, Cell Signaling Technology). To assess apoptosis, cells were exposed to inhibitor for 48 hours. After western blotting the following antibodies were used: anti-cleaved caspase-3 (#9664), anti-cleaved lamin A (#2031), anti-cleaved PARP (#9544) and anti-GAPDH (#2118), all from Cell Signaling Technology.
Primary patient material assays
Cryopreserved peripheral blood mononuclear cells from five EMS patients taken at or close to the time of diagnosis were used in in vitro response assays. 
Ponatinib inhibit proliferation and survival of primary cells from EMS patients
Primary cryopreserved cells from five patients with FGFR1 translocations were exposed to ponatinib in methylcellulose colony assays and growth compared to that seen in normal control samples. Overall, ponatinib treatment resulted in significantly reduced colony growth in patients compared with normal controls (t-test, p<0.05) ( Figure 3A ). Reductions were seen at all ponatinib concentrations ( Figure 3B ), but due to lower numbers the differences at each concentration were not statistically significant.
For cases 1, 4 and 5, colonies from day 14 plates were plucked for FISH analysis with Table 3 ).
In summary, we have shown that ponatinib has clear activity against FGFR1 fusion proteins in EMS and thus offers potential for the treatment of this rare subset of MPN patients for whom current therapy is inadequate.
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